22,135,656
Vote Records
28,570
Companies
12,092
Funds
3,981
Managers

Home › Companies › PROTAGONIST THERAPEUTICS INC. › 2024-2025

PROTAGONIST THERAPEUTICS INC. 2024-2025 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and PROTAGONIST THERAPEUTICS INC.’s Form 8-K, filed June 26, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 304Asset managers, any item
  • 1,453Fund votes
  • June 20, 2025Meeting date

Results at a glance

Meeting of June 20, 2025: 4 items on PROTAGONIST THERAPEUTICS INC.’s Form 8-K, filed June 26, 2025: 2 approved · 2 passed (calculated).

Dissent

Significant dissent: 1 director (21.3% against).

Notable dissent: 1 director (17.0% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore PROTAGONIST THERAPEUTICS INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by PROTAGONIST THERAPEUTICS INC.

These tallies are PROTAGONIST THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 26, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

PROTAGONIST THERAPEUTICS INC. — official shareholder meeting results, meeting held June 20, 2025
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Harold E. Selick, Ph.D. 44,822,907---- 9,210,0361,918,517 83%Passed (calculated)—
Elect Director: Bryan Giraudo 42,499,790---- 11,533,1531,918,517 79%Passed (calculated)—
2. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers 50,844,5172,850,473337,953 --1,918,517 95%Approved—
3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025 55,480,73974,233396,488 ---- 99.9%Approved—

Source: PROTAGONIST THERAPEUTICS INC., Form 8-K, filed with the SEC on June 26, 2025 — read the filing on EDGAR.

How asset managers voted at the PROTAGONIST THERAPEUTICS INC. 2024-2025 meeting

304 asset managers disclosed a vote on at least one PROTAGONIST THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Harold E. Selick, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

83% Majority: yes · of votes cast

FOR 83%WITHHELD
FOR: 44,822,907WITHHELD: 9,210,036
Details: description as filed, official tally, votes by 90 asset managers

Description as filed by funds: To elect the Class III director nominees named below to hold office until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Harold E. Selick, Ph.D.

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Elect Director: Harold E. Selick, Ph.D.”): 44,822,907 for, 9,210,036 withheld, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 83% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 90 asset managers below reported 15,056,041 for, 1,967,828 withheld, 672,052 abstained.

FOR
FOR: 15,056,041ABSTAIN: 672,052WITHHOLD: 1,967,828
Largest asset managers voting on “To elect the Class III director nominees named below to hold office until the 2028 Annual Meeting of Stockhold” at PROTAGONIST THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock4,414,6340 418,6620Mixed
Vanguard4,184,9450 122,864For
Fidelity1,813,5750 00For
State Street1,361,6890 01,813For
T. Rowe Price923,4200 00For
American Century00 0655,557Withhold
Charles Schwab506,7570 00For
Invesco392,3270 00For
JPMorgan266,8450 00For
Hartford195,8420 00For
Equitable107,5990 064,980Mixed
TIAA00 0146,001Withhold
Victory Capital00 0132,533Withhold
Columbia Threadneedle126,4200 00For
First Trust00 0111,012Withhold
Lincoln Financial65,8390 041,637Mixed
Jackson National00 104,0360Abstain
John Hancock49,6990 44,3220Mixed
Northwestern Mutual89,6340 00For
QUANTITATIVE MASTER SERIES LLC85,9630 00For
HUSSMAN INVESTMENT TRUST84,0000 00For
CARILLON SERIES TRUST00 81,9940Abstain
BNY Mellon00 066,306Withhold
DRIEHAUS MUTUAL FUNDS00 065,647Withhold
Voya62,4130 00For

Showing the 25 largest of 90 asset managers. All 90 are in the interactive database (link above).

Elect Director: Bryan Giraudo

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 6 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%WITHHELD
FOR: 42,499,790WITHHELD: 11,533,153
Details: description as filed, official tally, votes by 89 asset managers

Description as filed by funds: To elect the Class III director nominees named below to hold office until the 2028 Annual Meeting of Stockholders and until their successors are duly elected and qualified: Bryan Giraudo

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“Elect Director: Bryan Giraudo”): 42,499,790 for, 11,533,153 withheld, per its Form 8-K filed June 26, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 79% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 89 asset managers below reported 13,751,661 for, 3,198,245 withheld, 662,015 abstained.

FORWITHHOLD
FOR: 13,751,661ABSTAIN: 662,015WITHHOLD: 3,198,245
Largest asset managers voting on “To elect the Class III director nominees named below to hold office until the 2028 Annual Meeting of Stockhold” at PROTAGONIST THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock4,414,6340 418,6620Mixed
Vanguard4,184,9430 142,864For
Fidelity1,813,5750 00For
State Street1,361,6890 01,813For
T. Rowe Price923,4200 00For
American Century00 0655,557Withhold
Charles Schwab00 0506,757Withhold
Invesco00 0392,327Withhold
JPMorgan266,8450 00For
Hartford195,8420 00For
Equitable107,5990 064,980Mixed
TIAA00 0146,001Withhold
Victory Capital00 0132,533Withhold
Columbia Threadneedle00 0126,420Withhold
First Trust00 0111,012Withhold
Lincoln Financial65,8390 041,637Mixed
Jackson National00 104,0360Abstain
John Hancock49,6990 44,3220Mixed
Northwestern Mutual68,8850 020,749Mixed
QUANTITATIVE MASTER SERIES LLC85,9630 00For
CARILLON SERIES TRUST00 81,9940Abstain
BNY Mellon00 066,306Withhold
DRIEHAUS MUTUAL FUNDS00 065,647Withhold
Voya00 062,413Withhold
Principal5290 057,887Withhold

Showing the 25 largest of 89 asset managers. All 89 are in the interactive database (link above).

To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers

Official resultFund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

95% Approved · of votes cast

FOR 95%
FOR: 50,844,517AGAINST: 2,850,473

Prior year: 78.4% for (June 20, 2024 meeting) ▲ 16.3 pts

Details: description as filed, official tally, votes by 304 asset managers

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“2. To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers”): 50,844,517 for, 2,850,473 against — passed, per its Form 8-K filed June 26, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 90 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at PROTAGONIST THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock4,833,2960 00For
Vanguard4,184,9552,866 00For
Fidelity1,813,5750 00For
State Street1,362,829673 00For
T. Rowe Price923,4200 00For
American Century0655,557 00Against
Charles Schwab506,7570 00For
Invesco0392,327 00Against
JPMorgan266,8450 00For
Hartford195,8420 00For
Equitable172,5790 00For
TIAA146,0010 00For
Victory Capital132,5330 00For
Columbia Threadneedle126,4200 00For
First Trust111,0120 00For
Lincoln Financial97,6099,867 00Mixed
Jackson National104,0360 00For
John Hancock94,0210 00For
Northwestern Mutual89,6340 00For
QUANTITATIVE MASTER SERIES LLC85,9630 00For
HUSSMAN INVESTMENT TRUST084,000 00Against
CARILLON SERIES TRUST81,9940 00For
BNY Mellon66,3060 00For
DRIEHAUS MUTUAL FUNDS65,6470 00For
Voya62,4130 00For

Fund voting reports, all 90 managers: 16,490,374 for, 1,199,217 against, 6,330 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 239 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers.” at PROTAGONIST THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
RTW INVESTMENTS, LP5,685,8010 00For
FARALLON CAPITAL MANAGEMENT LLC4,690,5160 00For
Deep Track Capital, LP3,250,0000 00For
BVF INC/IL2,575,0150 00For
State Street2,512,64017,235 00For
BlackRock1,952,82122,891 00For
GEODE CAPITAL MANAGEMENT, LLC1,427,9140 00For
T. Rowe Price1,190,6090 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.1,120,1640 00For
ADAR1 Capital Management, LLC843,3800 00For
Wellington772,2010 00For
Lynx1 Capital Management LP733,0140 00For
Eversept Partners, LP669,7980 00For
American Century0668,104 00Against
Charles Schwab564,1610 00For
PERCEPTIVE ADVISORS LLC547,5620 00For
Northern Trust538,911526 00For
Invesco0538,745 00Against
Fidelity530,6490 00For
PICTET ASSET MANAGEMENT SA508,1310 00For
Woodline Partners LP480,6340 00For
JPMorgan445,9330 00For
BNP Paribas Asset Management Holding S.A.0354,697 00Against
PRINCIPAL GLOBAL INVESTORS351,0900 00For
Focus Partners Wealth327,4998 00For

Institutional-manager reports, all 239 managers: 36,678,330 for, 2,466,760 against, 327,521 abstained, 3,464 not voted. Showing the 25 largest; every one is in the interactive database (link above).

To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

99.9% Approved · of votes cast

FOR 99.9%
FOR: 55,480,739AGAINST: 74,233

Prior year: 99.8% for (June 20, 2024 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 91 asset managers

Description as filed by funds: To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025.

PROTAGONIST THERAPEUTICS INC.’s own tally for this item (“3. To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for its fiscal year ending December 31, 2025”): 55,480,739 for, 74,233 against — passed, per its Form 8-K filed June 26, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “This proposal was approved by the requisite vote, with the votes thereon as follows:”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 91 asset managers below reported 17,651,643 for, 40,199 against, 6,330 abstained.

FOR
FOR: 17,651,643AGAINST: 40,199ABSTAIN: 6,330
Largest asset managers voting on “To ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm fo” at PROTAGONIST THERAPEUTICS INC., 2024-2025
Asset managerForAgainst AbstainWithheldVote
BlackRock4,833,2960 00For
Vanguard4,187,8210 00For
Fidelity1,813,5750 00For
State Street1,363,5020 00For
T. Rowe Price923,4200 00For
American Century655,5570 00For
Charles Schwab506,7570 00For
Invesco392,3270 00For
JPMorgan266,8450 00For
Hartford195,8420 00For
Equitable172,5790 00For
TIAA146,0010 00For
Victory Capital132,5330 00For
Columbia Threadneedle126,4200 00For
First Trust111,0120 00For
Lincoln Financial107,4760 00For
Jackson National104,0360 00For
John Hancock94,0210 00For
Northwestern Mutual89,6340 00For
QUANTITATIVE MASTER SERIES LLC85,9630 00For
HUSSMAN INVESTMENT TRUST84,0000 00For
CARILLON SERIES TRUST81,9940 00For
BNY Mellon66,3060 00For
DRIEHAUS MUTUAL FUNDS65,6470 00For
Voya62,4130 00For

Showing the 25 largest of 91 asset managers. All 91 are in the interactive database (link above).

Largest PROTAGONIST THERAPEUTICS INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 61,928,760 shares outstanding at the time of that meeting.

Fund voting reports: top PROTAGONIST THERAPEUTICS INC. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1BlackRock 7.80%
2Vanguard 6.76%
3Fidelity 2.93%
4State Street 2.20%
5T. Rowe Price 1.49%
6American Century 1.06%
7Charles Schwab 0.82%
8Invesco 0.63%
9JPMorgan 0.43%
10Hartford 0.32%
Institutional-manager reports: top PROTAGONIST THERAPEUTICS INC. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2024-2025
#Asset manager % of shares outstanding
1RTW INVESTMENTS, LP 9.18%
2FARALLON CAPITAL MANAGEMENT LLC 7.57%
3Deep Track Capital, LP 5.25%
4BVF INC/IL 4.16%
5State Street 4.09%
6BlackRock 3.19%
7GEODE CAPITAL MANAGEMENT, LLC 2.31%
8T. Rowe Price 1.92%
9ADAGE CAPITAL PARTNERS GP, L.L.C. 1.81%
10ADAR1 Capital Management, LLC 1.36%

Reported PROTAGONIST THERAPEUTICS INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

PROTAGONIST THERAPEUTICS INC. holdings and ownership disclosed for the 2024-2025 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Entities affiliated with BlackRock, Inc.9,884,617 15.96%Proxy statement (DEF 14A), proxy filed April 29, 2025
BlackRock9,736,767 15.72%Form 13F, quarter ended March 31, 2025
Entities affiliated with Farallon Partners, L.L.C.6,210,006 10.03%Proxy statement (DEF 14A), proxy filed April 29, 2025
Farallon Partners, L.L.C.6,126,919 9.89%Schedule 13G, filed February 6, 2026
Entities affiliated with RTW Investments, L.P.5,315,514 8.58%Proxy statement (DEF 14A), proxy filed April 29, 2025
RTW Investments, LP5,059,053 8.17%Schedule 13G, filed February 17, 2026
Vanguard Group4,277,218 6.91%Form 13F, quarter ended March 31, 2025
Entities affiliated with The Vanguard Group4,216,081 6.81%Proxy statement (DEF 14A), proxy filed April 29, 2025
Vanguard Portfolio Management3,533,015 5.70%Schedule 13G, filed April 29, 2026
Entities affiliated with Deep Track Capital, LP3,250,000 5.25%Proxy statement (DEF 14A), proxy filed April 29, 2025

Percentages above are of 61,928,760 shares outstanding, as reported by PROTAGONIST THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At PROTAGONIST THERAPEUTICS INC.'s shareholder meeting held June 20, 2025, in the 2024-2025 proxy season, 304 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 1,453 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — PROTAGONIST THERAPEUTICS INC.'s filing reports the proposal as approved, with 95% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: PROTAGONIST THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 26, 2025.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from PROTAGONIST THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

PROTAGONIST THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Cite this page

Proxy Votes Now, “PROTAGONIST THERAPEUTICS (PTGX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/protagonist-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.